Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Investment analysts at Oppenheimer decreased their Q1 2018 earnings per share (EPS) estimates for Intercept Pharmaceuticals in a research note issued to investors on Thursday. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will post earnings of ($3.34) per share for the quarter, down from their previous forecast of ($3.07). Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for Intercept Pharmaceuticals’ Q2 2018 earnings at ($3.44) EPS, Q3 2018 earnings at ($3.19) EPS, Q4 2018 earnings at ($3.48) EPS, FY2018 earnings at ($13.45) EPS, FY2019 earnings at ($8.18) EPS, FY2020 earnings at ($5.76) EPS, FY2021 earnings at ($2.86) EPS and FY2022 earnings at ($0.66) EPS.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.39) by ($1.04). The firm had revenue of $37.69 million for the quarter, compared to the consensus estimate of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 207.27% and a negative net margin of 275.18%. The business’s revenue for the quarter was up 173.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($4.84) earnings per share.
Shares of Intercept Pharmaceuticals (NASDAQ ICPT) opened at $60.78 on Monday. The firm has a market capitalization of $1,530.00, a PE ratio of -4.23 and a beta of -2.13. Intercept Pharmaceuticals has a twelve month low of $51.05 and a twelve month high of $135.59. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15.
Several institutional investors and hedge funds have recently modified their holdings of ICPT. IFP Advisors Inc grew its position in shares of Intercept Pharmaceuticals by 90.9% in the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,182 shares during the period. DSC Advisors L.P. acquired a new position in shares of Intercept Pharmaceuticals in the 4th quarter valued at approximately $204,000. Amalgamated Bank acquired a new position in shares of Intercept Pharmaceuticals in the 4th quarter valued at approximately $209,000. Virtu Financial LLC acquired a new position in shares of Intercept Pharmaceuticals in the 4th quarter valued at approximately $234,000. Finally, Birchview Capital LP acquired a new position in shares of Intercept Pharmaceuticals in the 3rd quarter valued at approximately $250,000. Institutional investors and hedge funds own 78.39% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.